Key result
Viral proteases are valid molecular targets for the development of antiviral drugs, as demonstrated by the success of anti-HIV-1 therapy using specific protease inhibitors.
Viral proteases represent a promising target for the development of novel antiviral therapies.
May support protease inhibitor development for non-HIV viruses; leaves open clinical validation and specificity testing.
Proteases fulfill multiple roles in health and disease, and considerable interest has been expressed in the design and development of synthetic inhibitors of disease-related proteases. Virus-encoded proteases have been shown to be involved in the replication of many viruses. The success of anti-HIV-1 therapy using specific and potent protease inhibitors suggests that viral proteases can be the valid molecular targets for the development of antiviral drugs against other viruses. Intensive genetic and biochemical studies have been conducted on viral proteases and new insights and results are rapidly emerging. This work reviews features of viral proteases with respective to the development of effective antiviral therapy.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2006) conducted a review in Viral infections. Viral protease inhibitors was evaluated. Viral proteases are valid molecular targets for the development of antiviral drugs, as demonstrated by the success of anti-HIV-1 therapy using specific protease inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: